First Quarter 2014 Conference Call 29 April, 2014 SORIN GROUP Presentation 1
DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including information related to Sorin projected financial performance and the expected development of the med-tech industry, in particular in the cardiovascular segment. These statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, as of this date, though by their nature future estimates are uncertain and difficult to predict. Actual results or experience could differ materially from the information contained herein. This communication does not constitute an offer or solicitation for the sale, purchase or acquisition of securities of any of the companies mentioned in any jurisdiction. * * * Unaudited data SORIN GROUP Presentation 2
Q1 2014 RESULTS KEY ACHIEVEMENTS Data in m Revenues Q1 2014 176.3 Adjusted net profit 10.8 Q1 revenues in the high-end of the guidance (+1.8%* growth) Cardiac Surgery positive performance, driven by cardiopulmonary products segments and by Perceval TM CRM improving underlying sales performance Key business achievements JV with MicroPort Acquisition of Oscor s CRM leads business Investment program in New Ventures at expected pace FDA approval for Mitroflow TM PRT (in April) * At comparable FX and perimeter Adjusted net profit: net profit before after-tax non-recurring income and expenses (special items) SORIN GROUP Presentation 3
Q1 2014 RESULTS CARDIAC SURGERY: 115.4m (+4.3%*) Data in m and % Heart-lung machines Q1 2014 Revenues 21.5 Underlying growth* +16.0% Oxygenators 48.6 +3.2% Autotransfusion devices 15.0 +9.5% Heart-lung machines Strong revenue growth, primarily in the US, Japan and emerging markets Oxygenators Inspire roll-out in Europe and significant contribution of the cannulae business Autotransfusion devices Positive momentum in every major market Acquisition of the cardiac surgery cannulae manufacturing activities from Sorin s supplier BEL * At comparable FX rates and perimeter SORIN GROUP Presentation 4
Q1 2014 RESULTS CARDIAC SURGERY: 115.4m (+4.3%*) Data in m and % Mechanical Valves Q1 2014 Revenues 11.9 Underlying growth* -7.2% Tissue Valves 15.1-4.3% Mechanical Valves Continued shift toward tissue valves in developed countries Lower volumes in emerging markets Tissue Valves Weak performance of Mitroflow TM in the US and phasing in Japan Strong performance of Perceval TM CE mark for adult age indication for Perceval TM Dedicated reimbursement for Perceval TM in Germany as of January 1 st, 2014 Further investment in Cardiosolutions (percutaneous mitral repair) FDA approval for Mitroflow TM with Phospholipid Reduction Treatment (PRT) (in April) * At comparable FX rates and perimeter SORIN GROUP Presentation 5
Q1 2014 RESULTS CARDIAC RHYTHM MANAGEMENT: 60.3m (-2.4%*) Data in m and % Low Voltage Q1 2014 Revenues 35.4 Underlying growth* -4.7% High Voltage 22.0 0.0% Low voltage Impact of MRI compatibility in Japan Positive momentum in Europe thanks to KORA TM 100 and REPLY TM 200 High voltage Soft performance of the ICD segment Continued penetration of SonR TM in Europe Joint venture with MicroPort for CRM China Acquisition of Oscor CRM leads business, including a lead manufacturing facility in Dominican Republic, for approximately US$20 million Acquisition of a license of the Imricor Medical Systems technology for CRM applications * At comparable FX rates and perimeter SORIN GROUP Presentation 6
CARDIAC RHYTHM MANAGEMENT ACQUISITION OF OSCOR LEADS BUSINESS Deal structure Headquartered in Tampa (Florida, US), 400 employees, ISO certified and FDA registered manufacturing facilities in the US and in the Dominican Republic Fully integrated company developing and producing world-class cardiac leads and catheters Trends in the leads segment Devices increasingly sold as systems MRI compatibility IS4/DF4 Overall pricing pressure Strong growth in emerging countries where ASP are lower Oscor-branded and Sorin OEM bradycardia leads business (including MRI compatible leads) R&D agreement for the development of MRI compatible tachycardia and left ventricular leads Fully-equipped lead manufacturing facility in the Dominican Republic Rationale Ability to system validate cans and leads Ability to develop full MRI compatible leads Self manufactured leads in a low cost environment Together with the license of the Imricor technology for CRM applications, this acquisition will allow Sorin to develop high-quality value-driven MRI compatible standard systems SORIN GROUP Presentation 7
Q1 2014 RESULTS Gross Profit SG&A R&D Data in m Data in m Data in m 105.5 104.3 72.2 69.2 59.0% 59.2% 40.4% 39.2% 19.0 19.7 10.6% 11.2% Gross margin improvement due to manufacturing efficiencies, offsetting pricing pressure in CRM and negative impact of FX SG&A at constant FX rates decreased by 2.5% Increase of internal R&D spending Additional R&D in New Ventures SORIN GROUP Presentation 8
Q1 2014 RESULTS EBITDA EBIT before special items Adjusted net profit* Data in m Data in m Data in m 26.3 26.8 14.7% 15.2% 14.3 8.0% 15.5 8.8% 9.1 10.8 Negative FX impact Good operating leverage Special items negative for 1.2m On a run-rate basis interest expenses were flat Negative impact of FX of approximately 2.4 million * Adjusted net profit: net profit before special items, net of the related tax effects SORIN GROUP Presentation 9
Q1 2014 RESULTS NET DEBT Net Debt Evolution Data in m 106.9 95.6 March 31, 2013 March 31, 2014 Free cash flow negative for 2.5 million in Q1 2014, adversely impacted by a temporary increase in inventory and one-off investments related to the reconstruction of the Mirandola site Business development initiatives for 15.0 million in Q1 2014 European Investment Bank approval of a new medium-long term financing of 100 million Free cash flow: net profit+ depreciation, amortization and writedowns ± * working capital investments. This account is net of impact of special items SORIN GROUP Presentation 10
GUIDANCE & NEXT EVENTS Sorin expects revenues to grow from 3% to 5% at comparable FX rates in Q2 2014 compared to the same period of 2013 Sorin confirms 2014 full-year guidance Revenue growth of 3% to 5% at constant FX over 2013 Adjusted net profit* of 55-60m or adjusted EPS of 11.5-12.5 euro cents Shareholders Meeting on April 30, 2014 to resolve on: 2013 financial statements Buy-back program (up to 17.5m shares) New 2014-2016 Long-Term Incentive Plan Free capital increase (up to 23 million ordinary shares) * Adjusted net profit: net profit before special items, net of the related tax effects SORIN GROUP Presentation 11